Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cardiol Therapeutics Inc. (CRDL : NSDQ)

• Company Description    Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON. Number of Employees: 18

• Price / Volume Information    Yesterday's Closing Price: $1.32 Daily Weekly Monthly 20 Day Moving Average: 428,121 shares Shares Outstanding: 111.82 (millions) Market Capitalization: $147.60 (millions) Beta: 0.77 52 Week High: $1.71 52 Week Low: $0.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.94% -7.68% 12 Week 23.36% 14.04% Year To Date 38.39% 26.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2265 UPPER MIDDLE ROAD EAST SUITE 602 - OAKVILLE,A6 L6H 0G5 CAN ph: 289-910-0850 fax: - investor.relations@cardiolrx.com http://www.cardiolrx.com

• General Corporate Information    Officers David Elsley - Chief Executive Officer; President and Director Guillermo Torre - Chair and Director Bernard Lim - Chief Operating Officer Peter Pekos - Director Andrew Hamer - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 14161Y200 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 111.82 Most Recent Split Date: (:1) Beta: 0.77 Market Capitalization: $147.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -40.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -229.43 12/31/25 - -239.10 09/30/25 - -217.53 ROA 03/31/26 - -165.60 12/31/25 - -165.77 09/30/25 - -153.67 Current Ratio 03/31/26 - 4.39 12/31/25 - 4.16 09/30/25 - 3.89 Quick Ratio 03/31/26 - 4.39 12/31/25 - 4.16 09/30/25 - 3.89 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.16 12/31/25 - 0.11 09/30/25 - 0.07 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.32 12/31/25 - 0.49 09/30/25 - 1.01

Powered by Zacks Investment Research ©